News

Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results (28 September 2012)

Read the full announcment in PDF format

Novo Nordisk today announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On 9 August, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect.


Media:
Investors:
Mike Rulis Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573 Tel: (+45) 4442 4303
mike@novonordisk.com krop@novonordisk.com
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com
In North America:
Ken Inchausti Jannick Lindegaard
Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575
kiau@novonordisk.com jlis@novonordisk.com

Company Announcement No 60 / 2012

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •